Evolving treatment landscape for early and advanced pancreatic cancer.
Evolving treatment landscape for early and advanced pancreatic cancer.
复制标题
DOI：
10.4251/wjgo.v9.i7.281
复制
发表时间：
2017-07-15
影响因子：
3
通讯作者：
Cheung WY
中科院分区：
文献类型：
--
作者：
Lau SC;Cheung WY
胰腺导管腺癌是一种罕见的癌症，即使在早期疾病的背景下，疾病相关的死亡率也很高。直到最近，胰腺癌的死亡率基本保持相似，其中吉西他滨单药治疗是大多数疾病阶段的全身治疗的支柱。随着活性多药化疗方案（即FOLFIRINOX和吉西他滨加nab-紫杉醇）的发现，胰腺癌的治疗前景正在缓慢发展。FOLFIRINOX和吉西他滨加nab-紫杉醇目前被认为是转移性胰腺癌的标准一线治疗选择。正在进行研究，以调查这些相同的方案在辅助治疗中的效用。由于新辅助方法可能提高切除率和手术结局，因此这些治疗对前期疾病的潜力也正在局部晚期背景下积极研究。随着越来越多的新数据的出现，胰腺癌的管理预计将在未来几年发生重大变化。
Pancreatic ductal adenocarcinoma is an infrequent cancer with a high disease related mortality rate, even in the context of early stage disease. Until recently, the rate of death from pancreatic cancer has remained largely similar whereby gemcitabine monotherapy was the mainstay of systemic treatment for most stages of disease. With the discovery of active multi-agent chemotherapy regimens, namely FOLFIRINOX and gemcitabine plus nab-paclitaxel, the treatment landscape of pancreatic cancer is slowly evolving. FOLFIRINOX and gemcitabine plus nab-paclitaxel are now considered standard first line treatment options in metastatic pancreatic cancer. Studies are ongoing to investigate the utility of these same regimens in the adjuvant setting. The potential of these treatments to downstage disease is also being actively examined in the locally advanced context since neoadjuvant approaches may improve resection rates and surgical outcomes. As more emerging data become available, the management of pancreatic cancer is anticipated to change significantly in the coming years.
登录
查看更多内容
影响因子：
45.3
作者：
Gill, Sharlene;Ko, Yoo-Joung;Moore, Malcolm
通讯作者：
Moore, Malcolm
影响因子：
8.4
作者：
BAKKEVOLD, KE;ARNESJO, B;KAMBESTAD, B
通讯作者：
KAMBESTAD, B
DOI：
10.1093/jnci/86.8.625
发表时间：
1994-04-20
期刊：
JOURNAL OF THE NATIONAL CANCER INSTITUTE
影响因子：
--
作者：
EKBOM, A;MCLAUGHLIN, JK;FRAUMENI, JF
通讯作者：
FRAUMENI, JF
影响因子：
45.3
作者：
Byrski, Tomasz;Gronwald, Jacek;Narod, Steven
通讯作者：
Narod, Steven
影响因子：
120.7
作者：
Boyd, J;Sonoda, Y;Hoskins, WJ
通讯作者：
Hoskins, WJ